Company intelligence / Profile preview

Beijing Sangel Fang Sheng Venture Capital

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

Beijing Sangel Fang Sheng Venture Capital is an active healthcare/life sciences-focused VC, with equity investments including companies such as BeyondSpring (oncology) and Bioantibody (diagnostics/therapeutics). Its portfolio includes companies reporting clinical and commercial success in diagnostics and drug R&D.

Therapeutic areas: CardiovascularOncologyInfectious DiseasesImmunology
Modalities: AntibodySmall moleculeDiagnostic reagentBiologics
Industry: Investors

Partnerships

BeyondSpring (oncology, U.S. and China)BioantibodySuperC (nanotechnology for healthcare)

Beyond the preview

Go deeper on Beijing Sangel Fang Sheng Venture Capital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Sangel Fang Sheng Venture Capital.

Explore the full profile